GLPGF
vs
S&P 500
GLPGF
S&P 500
Over the past 12 months, GLPGF has outperformed S&P 500, delivering a return of +19% compared to the S&P 500's +14% growth.
Stocks Performance
GLPGF vs S&P 500
Performance Gap
GLPGF vs S&P 500
Performance By Year
GLPGF vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Galapagos NV
Glance View
Founded in 1999, Galapagos NV emerged from the rich scientific collaboration between the Netherlands and Belgium, initially as a joint venture between the Dutch company Crucell and the Flemish biotech company Tibotec. In its early years, Galapagos carved a niche for itself by focusing on the discovery of novel targets leading to the development of human proteins for medicines. Through its proprietary technological platforms, Galapagos identifies and validates these targets, setting the stage for developing small molecules that inhibit these specific proteins. This unique approach positions the company at the forefront of innovative drug discovery, primarily targeting inflammatory diseases, fibrosis, and other conditions where there is a significant unmet medical need. Revenue for Galapagos is generated through several streams, most notably from strategic partnership deals and potential milestone payments in the biotech sector. The heart of its business model lies in deep collaborations with major pharmaceutical companies like Gilead Sciences, which bolster its financial stability and provide mutual benefits in drug development ventures. Additionally, Galapagos advances its proprietary drug candidates in clinical trials, aiming to bring them to market and secure approval from regulatory bodies. By successfully moving these candidates through clinical development phases, it stands to secure substantial future revenue from both commercialization and licensing deals. With its innovative science-focused strategy, Galapagos continues to propel forward, endeavoring to transform scientific insights into tangible therapeutic advancements.
